Reviewer’s report

Title: Exceptional response to chemotherapy followed by concurrent radiotherapy and immunotherapy in a male with primary retroperitoneal serous adenocarcinoma: A case report and literature review.

Version: 0 Date: 22 Sep 2018

Reviewer: Zhihua Kang

Reviewer's report:

Primary retroperitoneal serous adenocarcinoma is a very rare type of human tumor with unclear pathogenesis and no established treatment. Here, the researchers show us that combined radiotherapy with nivolumab immunotherapy could effectively control the primary tumor and metastases, and benefit for the management of a male case with PRSA.

My only concern is that the researchers used circulating tumor and tissue DNA samples to find the potential mutations. For consideration of the link between PD-1 immunotherapy and mismatch repair deficiency is relative clear now. Did the mutations results contain the Mismatch repair genes mutations? If the tumor tissue DNA and tissue samples are preserved, the tumor microsatellite instability and the mutations and expression of mismatch repair genes should be analyzed.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics
Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal